Alessandro Gringeri

TL;DR: FEIBA and NovoSeven appear to exhibit a similar effect on joint bleeds, although the efficacy between products is rated differently by a substantial proportion of patients.

TL;DR: Prophylaxis was more effective when started early (≤36 months), with patients having fewer joint bleeds and arthropathy in children with hemophilia, particularly when it is initiated early in life.

TL;DR: Hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life, which is similar to that of patients with severe hemophilia without inhibitors.

TL;DR: Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference, and agreed upon revised definitions for primary and secondary Prophylaxis and made recommendations concerning the need for an international system of pharmacovigilance.

TL;DR: The need for randomized controlled trials to address whether or not the risk of inhibitor in PUPs with hemophilia A differs between rFV III and pdFVIII is underscored.